Researchers have discovered that an enzyme can serve as an ideal target for developing new therapeutics against Lyme disease, and most likely other tick-borne diseases as well. The finding was reported in mBio, a journal of the American Society for Microbiology.
Lyme disease is the most commonly reported tick-borne illness in the United States and Europe. Its causative pathogen, Borrelia burgdorferi, has evolved unique metabolic pathways to cope with its enzootic life cycle, some of which…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply